The financing provides Novocure with significant capital to support its operational and expansion plans without diluting current shareholders' equity. This strategic financial move is likely to be viewed positively by investors, as it demonstrates confidence in Novocure's growth trajectory and its ability to manage debt effectively. The focus on non-small cell lung cancer, a major area in oncology, could significantly enhance Novocure's market position if successful.